Merck & Co., Inc. (FRA:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 167.31B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 11.98 |
| Forward PE | 8.54 |
| Dividend | 2.91 (4.28%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 4,898 |
| Average Volume | 3,314 |
| Open | 67.30 |
| Previous Close | 66.70 |
| Day's Range | 66.50 - 67.40 |
| 52-Week Range | 65.50 - 103.60 |
| Beta | n/a |
| RSI | 35.92 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Merck: Game-Changing Oncology Drugs Power Stock Surge
Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-...
Merck: 25% Total Return CAGR Potential
Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like...
Merck's Keytruda gets an upgrade
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news.
Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape
CNBC's Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new va...
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AIDD--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeu...
FDA Clears Merck's One-Minute Cancer Shot
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE: MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration i...
Price Over Earnings Overview: Merck & Co
In the current market session, Merck & Co Inc. (NYSE: MRK) price is at $81.57, after a 0.07% spike. However, over the past month, the stock decreased by 4.02% , and in the past year, by 29.04% . Shar...
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff
The Food and Drug Administration approved an injectable version of Merck's biggest moneymaker, cancer behemoth Keytruda.
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
Merck trades at a deep discount to peers with strong profitability, Keytruda-led growth, and a 3.99% yield despite near-term risks. See why MRK stock is a strong buy.
Undercovered Dozen: Applied Digital, Merck, B2Gold And More
The Undercovered Dozen is a weekly Seeking Alpha editor-curated series highlighting 12 articles on lesser-covered stocks from the previous seven days.
Merck (MRK) Receives FDA Approval for New Keytruda Qlex Injection
Merck (MRK) Receives FDA Approval for New Keytruda Qlex Injection
FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidas...
FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYT...
Merck (MRK) Gains FDA Approval for Rapid Keytruda Qlex Delivery
Merck (MRK) Gains FDA Approval for Rapid Keytruda Qlex Delivery
FDA Approves New Administration Method for Merck's Keytruda (MRK)
FDA Approves New Administration Method for Merck's Keytruda (MRK)
Merck wins FDA approval for subcutaneous Keytruda: Endpoints
FDA approves Merck's Keytruda Qlex, a fast subcutaneous cancer drug alternative to IVs. Read more here.
Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug
On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.’s (NYSE: MRK) Keytruda (pembrolizumab) . One opinion recommends approval of a new subcutaneous (SC) administration rout...
US FDA approves Merck's new injectable version of Keytruda
The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient option of the wi...
Decoding Merck & Co's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE: MRK). And retail traders should know. We noticed this today when the trades showed up on publicly available opt...
Merck (MRK) Stock Sees Uptick Despite Target Price Downgrade
Merck (MRK) Stock Sees Uptick Despite Target Price Downgrade